Invasive Pleomorphic Lobular Carcinoma of the Breast: Clinicopathologic Characteristics and Prognosis Compared with Invasive Ductal Carcinoma

被引:30
作者
Jung, Seung Pil [1 ]
Lee, Se Kyoung [1 ]
Kim, Sangmin [1 ]
Choi, Min-Young [1 ]
Bae, Soo Youn [1 ]
Kim, Jiyoung [1 ]
Kim, Minkuk [1 ]
Kil, Won Ho [1 ]
Cho, Eun Yoon [2 ]
Choe, Jun-Ho [1 ]
Kim, Jung-Han [1 ]
Kim, Jee Soo [1 ]
Nam, Seok Jin [1 ]
Lee, Jeong Eon [1 ]
机构
[1] Sungkyunkwan Univ, Dept Surg, Samsung Med Ctr, Div Breast & Endocrine Surg,Sch Med, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea
关键词
Breast; Lobular carcinoma; Prognosis; CANCER; SURVIVAL; IMMUNOHISTOCHEMISTRY; INSTITUTION; FEATURES;
D O I
10.4048/jbc.2012.15.3.313
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Invasive pleomorphic lobular carcinoma (IPLC) is a very rare and distinct morphological variant of invasive lobular carcinoma (ILC), characterized by nuclear atypia and pleomorphism contrasted with the cytologic uniformity of ILC. This study evaluated clinicopathologic characteristics and prognosis of IPLC compared with invasive ductal carcinoma (IDC). Methods: We retrospectively reviewed the medical records of 35 patients with IPLC and 6,184 patients with IDC, not otherwise specified. We compared the clinicopathologic characteristics, relapse-free survival (RFS) and disease specific survival (DSS) of patients who were surgically treated between January 1997 and December 2010. Results: Patients with IPLC presented at an older age with larger tumor size, worse histologic grade, higher rates of N3 stage, more multifocal/multicentric tumors, and more nipple-areolar complex involvement than those of patients with IDC. During the follow-up period, the IPLC group experienced five cases (14.3%) of disease recurrence and three cases (8.6%) of disease specific mortality compared with 637 cases (10.4%) of recurrence and 333 cases (5.4%) of disease specific mortality in the IDC group. Univariate analysis using the Kaplan-Meier method revealed that the IPLC group showed a significantly poorer prognosis than that of the IDC group (RFS, p=0.008; DSS, p<0.001). However, after adjusting for clinicopathologic factors, a multivariate analysis showed no statistical differences in RFS(p=0.396) and DSS (p=0.168)between the IPLC and the IDC groups. Conclusion: Our data suggest that patients with IPLC present with poor prognostic factors such as large tumor size, poor histologic grade and advanced stage at diagnosis. These aggressive clinicopathologic characteristics may result in poor clinical outcomes. Although our study could not link IPLC histology to poor prognosis, considering the aggressive characteristics of IPLC, early detection and considerate treatment, including proper surgical and adjuvant intervention, could be helpful for disease progression and survival.
引用
收藏
页码:313 / 319
页数:7
相关论文
共 23 条
[1]  
Allred DC, 1998, MODERN PATHOL, V11, P155
[2]   Invasive lobular carcinoma: to grade or not to grade [J].
Bane, AL ;
Tjan, S ;
Parkes, RK ;
Andrulis, I ;
O'Malley, FP .
MODERN PATHOLOGY, 2005, 18 (05) :621-628
[3]  
Bentz JS, 1998, MODERN PATHOL, V11, P814
[4]   Is pleomorphic lobular carcinoma really a distinct clinical entity? [J].
Buchanan, Claire L. ;
Flynn, Laurie W. ;
Murray, Melissa P. ;
Darvishian, Farbod ;
Cranor, Milicent L. ;
Fey, Jane V. ;
King, Tari A. ;
Tan, Lee K. ;
Sclafani, Lisa M. .
JOURNAL OF SURGICAL ONCOLOGY, 2008, 98 (05) :314-317
[5]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[6]   PLEOMORPHIC LOBULAR CARCINOMA OF THE BREAST - AN AGGRESSIVE TUMOR SHOWING APOCRINE DIFFERENTIATION [J].
EUSEBI, V ;
MAGALHAES, F ;
AZZOPARDI, JG .
HUMAN PATHOLOGY, 1992, 23 (06) :655-662
[7]   Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas [J].
Frolik, D ;
Caduff, R ;
Varga, Z .
HISTOPATHOLOGY, 2001, 39 (05) :503-513
[8]   Breast carcinoma in elderly women -: Features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients [J].
Gennari, R ;
Curigliano, G ;
Rotmensz, N ;
Robertson, C ;
Colleoni, M ;
Zurrida, S ;
Nolé, F ;
de Braud, F ;
Orlando, L ;
Leonardi, MC ;
Galimberti, V ;
Intra, M ;
Veronesi, P ;
Renne, G ;
Cinieri, S ;
Audisio, RA ;
Liuini, A ;
Orecchia, R ;
Viale, G ;
Goldhirsch, A .
CANCER, 2004, 101 (06) :1302-1310
[9]   Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J].
Harvey, JM ;
Clark, GM ;
Osborne, CK ;
Allred, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1474-1481
[10]  
HERBSMAN H, 1981, CANCER-AM CANCER SOC, V47, P2358, DOI 10.1002/1097-0142(19810515)47:10<2358::AID-CNCR2820471006>3.0.CO